Neurological and Autoimmune Solutions
Founded 1928
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
UCB's solutions line addressing neurological and autoimmune conditions, delivered through its global biopharmaceutical portfolio.
UCB is a global biopharmaceutical leader focused on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions. Its offering line spans medicines for these disease areas plus patient-support services such as UCBCares, a personalized service supporting patients and healthcare professionals during treatment with a UCB medicine.
UCB's public site presents its disease-area solutions across neurology, including epilepsy and rare diseases such as TK2d, and autoimmune conditions such as hidradenitis suppurativa, alongside resources for women of childbearing age. The company's neurological and autoimmune focus anchors this solutions line on its global site.
| Attribute | Neurological and Autoimmune Solutions | Exeltis — Central Nervous System | |
|---|---|---|---|
| Provider | |||
| Founded | 1928 | 2003 | |
| Sells To | Enterprise | — | |
| Pricing Model | Recurring, Software | — | |
| Ownership | Public | — |
Founded 1928
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 2003
Sells To —
Pricing Model —
Ownership —


Supernus commercial portfolio of products treating neurological and psychiatric conditions including ADHD, epilepsy, Parkinson's disease, and migraine.


Lundbeck's portfolio of registered therapies for neurological and psychiatric brain diseases, marketed across more than 80 countries.
Supernus commercial portfolio of products treating neurological and psychiatric conditions including ADHD, epilepsy, Parkinson's disease, and migraine.

Lundbeck's portfolio of registered therapies for neurological and psychiatric brain diseases, marketed across more than 80 countries.
